HK2 and neoplasm: Such as, several HK inhibitors, including the catalytic inhibitors 3-Bromopyruvate (3-BrPyr), Lonidamine, and the glucose-analogue, competitive inhibitor 2-Deoxyglucose (2-DG) both target HK2 in many tumor models, detach it from mitochondria and elicit tumor cell death (Garcia et al., 2019).